| abstract |
ALK1 ligand antagonists and such antagonists as anti-angiogenic agents are provided. A soluble ALK1 fusion protein of a polypeptide comprising the ligand binding portion of the extracellular domain of an activin-like kinase I (ALK1) polypeptide and an Fc domain. An antibody that binds to an ALK1 polypeptide and inhibits the binding of an ALK1 ligand to a receptor. A pharmaceutical preparation for inhibiting angiogenesis. [Selection figure] None |